In Vitro Toxicology Testing Market, valued at $10.8 billion in 2023, is projected to soar to $17.1 billion by 2028, boasting a robust compound annual growth rate (CAGR) of 9.5% during the forecast period. This remarkable expansion is fueled by the advent of cutting-edge toxicology testing technologies and heightened investment in research and development for early toxicity detection. The market's growth trajectory is further propelled by its alignment with stringent regulations banning animal testing, leading to significant industry expansion over the past decade.
Our comprehensive research delves deep into industry trends, conducts meticulous pricing analysis, scrutinizes patents, gleans insights from conferences and webinars, identifies key stakeholders, and provides a nuanced understanding of market dynamics. Embracing promising new technologies, our solutions offer revolutionary testing methodologies, ensuring compliance with regulatory mandates while fostering sustainable testing practices. With unparalleled growth projections, our offerings present strategic investment opportunities, driving accelerated market adoption and optimized testing strategies.
Download an Illustrative overview
Browse in-depth TOC on "In Vitro Toxicology Testing Market"
392 - Tables
52- Figures
430 – Pages
Key Market Players of In Vitro Toxicology Testing Industry:
Key players in the in vitro toxicology testing market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), SGS SA (Switzerland), Bio-Rad Laboratories, Inc. (US), Evotec SE (Germany), Promega Corporation (US), Catalent, Inc. (US), Agilent Technologies, Inc. (US), Intertek Group plc (UK), Revvity (US), Inotiv (US), BioIVT (US), Lonza (Switzerland), Creative Biolabs (US), Shanghai Medicilon Inc. (China), Creative Bioarray (US), Aragen Life Sciences Ltd. (India), Enzo Biochem Inc. (US), Microbac Laboratories, Inc. (US), Vimta Labs Ltd. (India), Pacific BioLabs Inc. (US), and MB Research Laboratories (US).
In Vitro Toxicology Testing Market Dynamics:
Drivers:
- Growing public resistance against animal testing
- Technological advancements
- Research and development efforts aimed at early-stage toxicity detection
Restraints:
- Resistance of certain regulatory bodies to embrace alternative approaches in toxicology testing
- Failure to establish intricacies of in vivo conditions
- Lack of in vitro models to study complex endpoints
Opportunities:
- Growing focus on drug discovery and personalized medicine using in vitro methods
- Increasing number of toxicology databases
- Increasing focus on predictive toxicology
Challenge:
- Lack of data availability and validation
- Complexity in data analysis and management
The consumables segment accounted for the largest share by product & service in the In vitro toxicology testing market in 2022.
By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services. Consumables accounted for the largest share of the in vitro toxicology testing market in 2022. The large share of this segment can be attributed to the increasing demand for high-quality reagents and the repeated use of media and reagents in in vitro toxicology studies. Additionally, the growing R&D activities in the pharmaceutical industry and the increased initiatives by governments in various countries to strengthen their product safety assessment capabilities are supporting the growth of this market.
The organ toxicity segment is expected to grow at a higher rate during the forecast period.
Based on the toxicity endpoints and tests, the in vitro toxicology testing market has been segmented into absorption, distribution, metabolism, and excretion (ADME), skin irritation, corrosion, and sensitization, genotoxicity, cytotoxicity, ocular toxicity, organ toxicity, phototoxicity, dermal toxicity, and other toxicity endpoints & tests. In 2022, the ADME segment accounted for the largest share of the in vitro toxicology testing market. However, the organ toxicity segment is expected to grow at a higher growth rate during the forecast period of 2023-2028. This can be attributed to increasing regulatory demands for safety assessment and reducing animal testing, continuous advancements in cell culture and tissue engineering technologies, and increasing drug development needs.
The pharmaceutical & biopharmaceutical segment accounted for the largest share of the industry segment in the in vitro toxicology testing market in 2022.
Based on industry, the in vitro toxicology testing market has been segmented into pharmaceutical & biopharmaceutical, consumer care, food, and other industries (including chemical and medical device industries). In 2022, the pharmaceutical & biopharmaceutical industry segment accounted for the largest share of the in vitro toxicology testing market. One of the major factors driving the growth of this segment is the mandate of preclinical safety assessment for the marketing approval of pharmaceutical products. Additionally, the rising investments in discovering new ways to construct molecules to study genetics and proteins and the increasing focus on reducing economic losses due to drug failures in the late stage are expected to increase the demand for in vitro tests to screen potentially toxic molecules during drug development.
The cell culture technologies segment accounted for the largest share of the technologies segment in the in vitro toxicology testing market in 2022.
Based on the technologies, the in vitro toxicology testing market has been segmented into cell culture, high-throughput screening, and toxicogenomics. In 2022, cell culture technologies accounted for the largest share. This can be attributed to the fact that it is the most preferred technique for toxicity testing owing to its capability of mimicking in vivo conditions. Cell and tissue-based technologies are commonly employed for in vitro toxicology testing in pharmacology. Cell cultures, either bacterial or mammalian, can express the same genes and proteins as their in vivo counterparts. Their ability to produce similar testing environments is one of the major factors driving the growth of this segment.
The Europe region catered for the largest share of the in vitro toxicology testing market in 2022.
The in vitro toxicology testing market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA). The European region is witnessing increasing investments to develop biologics and advanced dosage forms, with the impending patent expiration of several blockbuster drugs. The need to reduce the time and cost incurred to bring a drug to market—roughly 10 to 12 years, has contributed to the demand for in vitro toxicology testing of drugs.
Recent Developments:
- In March 2023, Agilent Technologies, Inc. (US) acquired e-MSion (US). Through this acquisition, Agilent will integrate the e-MSion's ExD cell into its portfolio of advanced workflows, instruments, and analytical solutions for biotherapeutic characterization and development.
- In January 2023, Eurofins Scientific expanded its presence in India with the establishment of a new, fully equipped, state-of-the-art laboratory campus in Genome Valley, Hyderabad. The lab will support pharma and biotech companies in the areas of synthetic organic chemistry, analytical R&D, bioanalytical services, in vivo pharmacology, safety toxicology, and formulation R&D.
Get 10% Free Customization on this Report
In Vitro Toxicology Testing Market Advantages:
- Ethical Considerations: In vitro testing methods are more humane and align with ethical concerns by reducing or eliminating the need for animal testing, thereby reducing harm to animals.
- Cost Efficiency: In vitro testing is often more cost-effective than in vivo testing, as it requires fewer resources, less time, and lower maintenance expenses.
- Rapid Results: In vitro tests can deliver results more quickly, allowing for faster decision-making in drug development, chemical safety assessments, and other applications.
- High Throughput: In vitro testing methods can be automated and conducted at a high throughput, making them suitable for screening large numbers of compounds or chemicals efficiently.
- Reduced Variability: In vitro tests offer greater control over experimental conditions, minimizing the variability often associated with in vivo tests.
- Human-Relevant Data: In vitro models can be designed to mimic human biology more closely, providing more relevant data for predicting human responses to drugs and chemicals.
- Reduced Safety Risks: In vitro testing reduces the potential risks associated with handling and testing in live animals, improving laboratory safety.
- Regulatory Acceptance: Regulatory agencies increasingly accept and encourage in vitro toxicology testing data for safety assessments, streamlining the approval process for pharmaceuticals and chemicals.
- Environmental Benefits: Reduced animal testing leads to fewer ecological impacts, such as reduced use of laboratory animals and fewer waste disposal concerns.
- Adaptability: In vitro testing can be tailored to specific research needs, enabling customization for different applications and industries.
Content Source:
https://www.marketsandmarkets.com/Market-Reports/in-vitro-toxicology-testing-market-209577065.html
https://www.marketsandmarkets.com/PressReleases/in-vitro-toxicology-testing.asp
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek